HJB, a biologics contract development and manufacturing organization (CDMO), has entered into a partnership for CMC development and manufacturing with Ansun Biopharma on its therapeutic biologics pipeline. The first program is expecting to submit an Investigational New Drug (IND) application in 2021.
HJB, a biologics contract development and manufacturing organization (CDMO) committed to quality, reliability and speed for each and every CMC package delivered to its partners, announces it enters into a strategic partnership for CMC development and manufacturing with Ansun Biopharma, a clinical stage biopharmaceutical company, on its therapeutic biologics pipeline. The first program is expecting to submit an Investigational New Drug (IND) application in 2021.
CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (NASDAQ: ATHX) announced today that the U.S. Food and Drug Administration (FDA) has authorized an Investigational New Drug (IND) application to initiate a Phase 2 clinical trial evaluating Athersys’ MultiStem® cell therapy for early treatment of traumatic injuries and the subsequent complications that result following severe trauma. The trial will be conducted by The University of Texas Health Science Center at Houston (UTHealth) at Memorial Hermann-Texas Medical Center in Houston, Texas, one of the busiest Level 1 trauma centers in the United States. The study represents another important application of the company’s MultiStem cell therapy in the critical care area, targeting the severe inflammatory responses associated with poor outcomes.
San Diego-based Ansun Biopharma recently closed an $80 million Series B funding round, led by China Investors, according to ChinaBio Today. The funds will be used to help advance the company’s lead antiviral, which already been granted fast track eligibility and breakthrough therapy status by the FDA in the US and is being reviewed for the treatment of lower respiratory tract infections caused by parainfluenza virus (PIV) in immunodeficient patients.
Ansun Biopharma , which is committed to developing first-in-class innovative biopharmaceuticals for the most urgent and unmet clinical needs in the field of respiratory infections, announced the completion of a $80 million Series B round of financing. This round of financing was led by Haisong Capital, Dawan District Common Home Development Fund, Jiachen Capital, KIP and existing shareholders Yuanming Capital, Lilly Asia Fund, Jingwei China, Materia Medica Capital, and Jifeng Capital. Huaxing Capital acted as the exclusive financial advisor for this financing.